Dexco 관리

Mr. Antonio Joaquim de Oliveira has been the Chief Executive Officer at Duratex S.A since April 2013 and served as its Director of Investor Relations since August 15, 2016 until May 1, 2017. He serves as M...

리더십 팀

이름	위치	테뉴어	보상	소유권
Antonio de Oliveira	CEO & Member of Executive Board	15.3yrs	데이터 없음	데이터 없음
Francisco Augusto Neto	Director of Finance	no data	데이터 없음	데이터 없음
Carlos Henrique Haddad	VP of Wood Division & Member of Management Board	no data	데이터 없음	데이터 없음
Glizia do Prado	People Director & Member of Executive Board	no data	데이터 없음	데이터 없음
Raul Guaragna	VP, Director of Deca & Coatings Division and Member of Executive Board	no data	데이터 없음	데이터 없음
Daniel Franco	IT & Growth Director and Member of Executive Board	no data	데이터 없음	데이터 없음
Marco Milleo	Deca Industrial Director	no data	데이터 없음	데이터 없음
José Ricardo Ferraz	Operations Director of the Wood Division	7.1yrs	데이터 없음	데이터 없음
Gilmar Menegon	Ceramic Tiles Director	6.8yrs	데이터 없음	데이터 없음
Marcelo Jose Izzo	Executive VP & Head of Deca	no data	데이터 없음	데이터 없음
Natasha Utescher	Investor Relations Manager	no data	데이터 없음	데이터 없음
Felipe Saraiva	Investor Relations Coordinator	no data	데이터 없음	데이터 없음

7.1yrs

평균 재임 기간

경험이 풍부한 관리: DXCO3 의 관리팀은 노련하고 경험 (평균 재직 기간 7.1 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Alfredo Setubal	Chairman	7.7yrs	데이터 없음	데이터 없음
Alfredo Arruda Villela Filho	Vice Chairman	28.8yrs	데이터 없음	데이터 없음
Raul de Oliveira Neto	Member of Fiscal Council	no data	데이터 없음	데이터 없음
Rodolfo Villela Marino	Director	7.7yrs	데이터 없음	데이터 없음
Ricardo Setubal	Director	16.6yrs	데이터 없음	데이터 없음
Alexandre de Barros	Substitute Member	4.3yrs	데이터 없음	데이터 없음
Helio Seibel	Vice Chairman	7.7yrs	데이터 없음	데이터 없음
Andrea Seibel	Director	3.8yrs	데이터 없음	데이터 없음
Juliana Munemori	Independent Director	no data	데이터 없음	데이터 없음
Guilherme Pereira Junior	President of Fiscal Council	6.5yrs	데이터 없음	데이터 없음
Paula Setubal	Substitute Member	4.5yrs	데이터 없음	데이터 없음
Marcio Torres	Independent Director	4.8yrs	데이터 없음	데이터 없음

7.1yrs

평균 재임 기간

58.5yo

평균 연령

경험이 풍부한 이사회: DXCO3 의 이사회는 경험(평균 재직 기간 7.1 년)으로 간주됩니다.

Dexco 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Dexco S.A., Annual General Meeting, Apr 26, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

New minor risk - Profit margin trend

Third quarter 2024 earnings: Revenues exceed analyst expectations

Is Dexco (BVMF:DXCO3) A Risky Investment?

Consensus EPS estimates fall by 14%

Dexco S.A.(BOVESPA:DXCO3) dropped from FTSE All-World Index (USD)

Consensus EPS estimates fall by 16%

Analysts Are Updating Their Dexco S.A. (BVMF:DXCO3) Estimates After Its Second-Quarter Results

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Why Dexco S.A. (BVMF:DXCO3) Could Be Worth Watching

Returns On Capital At Dexco (BVMF:DXCO3) Have Stalled

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Earnings Miss: Dexco S.A. Missed EPS And Analysts Are Revising Their Forecasts

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 26%

Is It Time To Consider Buying Dexco S.A. (BVMF:DXCO3)?

Consensus EPS estimates fall by 37%, revenue upgraded

Slowing Rates Of Return At Dexco (BVMF:DXCO3) Leave Little Room For Excitement

Dexco's (BVMF:DXCO3) Earnings Might Not Be As Promising As They Seem

Consensus EPS estimates increase by 19%, revenue downgraded

New minor risk - Earnings quality

New minor risk - Share price stability

Full year 2023 earnings: EPS exceeds analyst expectations

Now 25% overvalued after recent price rise

Dexco S.A. to Report Q4, 2023 Results on Mar 06, 2024

Dexco S.A.'s (BVMF:DXCO3) Earnings Are Not Doing Enough For Some Investors

Dexco S.A., Annual General Meeting, Apr 26, 2024

Dexco (BVMF:DXCO3) Has A Somewhat Strained Balance Sheet

At R$7.43, Is Dexco S.A. (BVMF:DXCO3) Worth Looking At Closely?

Consensus EPS estimates increase by 12%, revenue downgraded

Consensus EPS estimates increase by 45%, revenue downgraded

Price target decreased by 8.5% to R$9.82

Returns Are Gaining Momentum At Dexco (BVMF:DXCO3)

Is Dexco (BVMF:DXCO3) A Risky Investment?

Second quarter 2023 earnings released

Consensus EPS estimates increase by 19%

Consensus EPS estimates increase by 22%

Returns At Dexco (BVMF:DXCO3) Are On The Way Up

Consensus EPS estimates increase by 10%

Does Dexco (BVMF:DXCO3) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 13%

Investor sentiment improves as stock rises 24%

First quarter 2023 earnings released: EPS: R$0.18 (vs R$0.27 in 1Q 2022)

Consensus EPS estimates increase by 12%, revenue downgraded

Consensus EPS estimates increase by 15%

Investor sentiment deteriorates as stock falls 16%

Consensus EPS estimates fall by 24%

Price target decreased by 10% to R$10.91

We Like These Underlying Return On Capital Trends At Dexco (BVMF:DXCO3)

Price target decreased by 10.0% to R$12.65

We Think Dexco (BVMF:DXCO3) Is Taking Some Risk With Its Debt

Dexco (BVMF:DXCO3) Might Have The Makings Of A Multi-Bagger

Price target decreased to R$15.76

Less than half of directors are independent

We Think Dexco (BVMF:DXCO3) Is Taking Some Risk With Its Debt

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues miss analyst expectations

Consensus EPS estimates increase by 28%

Is Now The Time To Look At Buying Dexco S.A. (BVMF:DXCO3)?

Investors Will Want Dexco's (BVMF:DXCO3) Growth In ROCE To Persist

We Think Dexco (BVMF:DXCO3) Is Taking Some Risk With Its Debt

Consensus EPS estimates fall by 10%

Second quarter 2022 earnings released

Is There Now An Opportunity In Dexco S.A. (BVMF:DXCO3)?

First quarter 2022 earnings: Revenues exceed analyst expectations

There's Been No Shortage Of Growth Recently For Dexco's (BVMF:DXCO3) Returns On Capital

Consensus forecasts updated

Is Dexco (BVMF:DXCO3) Using Too Much Debt?

Less than half of directors are independent

Here's Why I Think Dexco (BVMF:DXCO3) Is An Interesting Stock